New drug combo aims to stop lung Cancer's return after surgery
NCT ID NCT06624059
Summary
This study is testing whether adding the drug alectinib to standard chemotherapy helps prevent cancer from returning in people with early-stage, ALK-positive non-small cell lung cancer. It is testing two approaches: giving the drugs after surgery or before surgery. The main goals are to see if the treatment is safe and if it effectively clears cancer from the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
Perugia, Umbria, 06156, Italy
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Guangdong General Hospital
Guangzhou, 510000, China
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000, Brazil
-
Jinhua municipal central hospital
Jinhua, China
-
RedSalud Vitacura
Santiago, Chile
-
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
The third people's hospital of Chengdu
Chengdu, China
-
Yunnan Cancer Hospital
Kunming, 650118, China
Conditions
Explore the condition pages connected to this study.